|
Match
|
Document |
Document Title |
|
|
5654005 |
Controlled release formulation having a preformed passageway
A controlled release pharmaceutical tablet having at least one passageway, said tablet having: (a) a compressed core which comprises: (i) a medicament; (ii) an amount of a water soluble...
|
|
|
5651983 |
Bisacodyl dosage form for colonic delivery
The present invention relates to a pharmaceutical composition in a unit dosage form for peroral administration in a human or lower animal, having a gastrointestinal tract comprising a small...
|
|
|
5650168 |
Tablet with improved bioavailability containing dichloromethylenediphosphonic acid as the active substance
The invention concerns tablets with improved bioavailability of the active substance dichloromethylenediphosphonic acid or of a physiologically tolerated salt thereof and with a content of...
|
|
|
5650170 |
Dosage form for delivering drug at a controlled rate to the intestine and to the colon
A drug delivery device is disclosed for delivering a drug to the intestine and the colon. The device comprises external means for delaying the delivery of drug in the stomach, and hydrophobic means...
|
|
|
5641513 |
Tablet coating method
A method for coating pharmaceutical tablets is disclosed in which polymeric coating ingredients are combined with saccharides in a melt spinning operation to form composite particulates. The...
|
|
|
5637320 |
Controlled absorption naproxen formulation for once-daily administration
A once-daily naproxen formulation for oral administration having a first portion of the naproxen as a multi-particulate pellet form, each pellet having a core of naproxen or a pharmaceutically...
|
|
|
5637309 |
Physiologically active substance-prolonged releasing-type pharmaceutical preparation
A prolonged releasing pharmaceutical preparation is provided carrying a physiologically active substance, particularly, calcitonin gene-related peptide (CGRP) or a maxadilan (MAX). This...
|
|
|
5633000 |
Subcutaneous implant
A non-abusable, non-inflammatory, biocompatible, non-biodegradable, subcutaneous, polymeric implant for the prolonged, controlled release of hydromorphone with near zero-order kinetics is...
|
|
|
5629018 |
Composition for controlled release of an active substance and method for the preparation of such a composition
In a composition for delayed release of an active substance, the active substance is incorporated in a polysaccharide matrix which consists of an essentially crystalline straight-chain glucan and...
|
|
|
5628993 |
Sustained releasable parenteral pharmaceutical preparations and method of producing the same
A parenteral pharmaceutical preparation comprises a matrix containing a physiologically active peptide or protein and a polyglycerol diester of a saturated fatty acid, and the matrix is in a solid...
|
|
|
5626876 |
Floating system for oral therapy
The invention relates to a floatable, oral, therapeutic system, in which a lengthening of the gastrointestinal residence time of medicaments and a controlled delivery thereof are achieved by...
|
|
|
5624683 |
Sustained-release multi-granule tablet
A sustained-release multi-granule tablet is obtained by compressing sustained-release granules, which contains a basis, and a formulation adjuvant. Each of the granules has been coated in advance...
|
|
|
5618559 |
Method of making modified-release metronidazole compositions
Pharmaceutical compositions having a modified release profile for once daily dosing of metronidazole, methods for making the pharmaceutical compositions, and methods for treating a microbial...
|
|
|
5618803 |
Targeted drug delivery via phosphonate derivatives
The invention provides compounds of the formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein [D] is the residue of a drug having a reactive functional group, said functional...
|
|
|
5616345 |
Controlled absorption diltiazen formulation for once-daily administration
A diltiazem pellet formulation for oral administration comprises a core of diltiazem or a pharmaceutically acceptable salt thereof in association with an organic acid, and a multi-layer membrane...
|
|
|
5614219 |
Oral administration form for peptide pharmaceutical substances, in particular insulin
A peroral administration form for peptidic medicaments contains the peptidic medicament, in particular insulin, distributed in a gelatine or gelatine derivate matrix, besides usual pharmaceutical...
|
|
|
5609590 |
PH-triggered osmotic bursting delivery devices
An osmotic bursting device for dispensing a beneficial agent to an aqueous environment. The device comprises a beneficial agent and osmagent surrounded at least in part by a semipermeable membrane....
|
|
|
5607695 |
Process for the manufacture of porous cellulose matrices
A process for the manufacture of porous cellulose particles, which have regular shape, and a capacity of sorbing 1.5-9 times of their own weight of water, a tap bulk density of less than 0.85 g/ml...
|
|
|
5603957 |
Microcapsules for the controlled release of acetylsalicyclic acid in the gastrointestinal environment
The present invention relates to controlled-release microcapsules of acetylsalicylic acid which comprise particles of acetylsalicylic acid with a size of between 100 and 1000 μm, coated with a...
|
|
|
5603953 |
Supported liquid membrane delivery devices
Supported liquid membrane delivery devices that release a beneficial agent to an aqueous environment following exposure to an environmental trigger. A microporous hydrophobic support membrane at...
|
|
|
5593694 |
Sustained release tablet
A sustained release tablet comprising a base tablet comprising a water-swellable gelling agent and a pharmaceutically active ingredient dispersed homogeneously in said gelling agent, said base...
|
|
|
5594013 |
Pharmaceutical compositions containing nifedipine and process for the preparation thereof
This invention relates to a slow release nifedipine-containing pharmaceutical compositions and methods of making such compositions. The compositions of the inventions comprise a soluble carrier...
|
|
|
5582837 |
Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
Sustained release oral drug dosage forms that comprise a tablet or capsule containing a plurality of particles of a solid-state drug dispersed in alkyl cellulose such as hydroxyethylcellulose or...
|
|
|
5573776 |
Oral osmotic device with hydrogel driving member
An osmotic device (10) for delivering an ergot alkaloid into the mouth of a human patient is disclosed. The device (10) has a size and shape adapting it to be comfortably retained in the mouth for...
|
|
|
5569469 |
Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate
A poorly soluble medicament is incorporated into particles of a crosslinked polymer which is swellable in water but insoluble in water, and the product obtained is brought into contact with a...
|
|
|
5567439 |
Delivery of controlled-release systems(s)
The present invention is a method and a dosage unit for delivery of a controlled-release system. The dosage unit is a quick dissolve unit which can be prepared by mixing uncured shearform matrix...
|
|
|
5562919 |
Dried animal plasma as a pharmaceutical excipient for compressed tablet formulation
This invention relates to the use of purified spray dried animal plasma as a binder for tablet pharmaceutical compositions. Spray dried plasma demonstrates good tablet formation as a direct...
|
|
|
5560930 |
Method for preparing aqueous emulsion for coating solid pharmaceutical preparations
A method permits the easy preparation of an aqueous emulsion for coating solid pharmaceutical preparations through emulsification in water without addition of additives such as emulsifying agents,...
|
|
|
5560928 |
Nutritional and/or dietary composition and method of using the same
A composition and method of using the same which provides in as little as a single dose covering a 24 hour period a nutritional and/or dietary supplement which provides administration of water...
|
|
|
5560921 |
Chewable decongestant compositions
The present invention relates to immediate release compositions comprising a pre-complex comprising a polymeric polycarboxylate and an aminophenylalkanol vasoconstrictor in a solid chewable matrix...
|
|
|
5558879 |
Controlled release formulation for water soluble drugs in which a passageway is formed in situ
A controlled release pharmaceutical tablet is disclosed which is based on: (a) a compressed core which contains: (i) a medicament; (ii) from 5 to 20% by weight of a water soluble osmotic...
|
|
|
5556638 |
Flurbiprofen-containing immediate-effect medicament and its use
A medicament for immediately treating painful, inflammatory and/or febrile acute diseases contains flurbiprofen as a racemate, a mixture of a racemate with its enantiomers, a pseudoracemate...
|
|
|
5552152 |
Taste masking of ibuprofen by fluid bed coating
A chewable taste-masked ibuprofen tablet having controlled release characteristics.
|
|
|
5549911 |
Galenic form of 5-nitromidazole derivatives which is effective for the treatment of parasitoses and infections of the entire gastrointestinal tract
The present invention relates to a galenic form of 5-nitroimidazole derivatives which is characterized in that it comprises a combination of microgranules of 5-nitroimidazole derivatives...
|
|
|
5549891 |
Method for disinfecting contact lens with catalase compositions
Compositions and methods for destroying hydrogen peroxide in hydrogen peroxide-containing liquid aqueous media, for example, employed to disinfect contact lenses, are disclosed. In one embodiment,...
|
|
|
5543156 |
Bioerodible devices and compositions for diffusional release of agents
The present invention is directed to erodible delivery devices and to the compositions comprising the devices. The devices comprise (a) a body formed of a bioerodible polymer or polymers together...
|
|
|
5543155 |
Diffusion-osmotic controlled drug-release pharmaceutical composition and process for preparing same
The invention relates to a novel diffusion-osmotic controlled drug-release pharmaceutical composition containing a one-layer tablet core including a polymeric film-coat, a therapeutically active...
|
|
|
5538734 |
5-methyltetrahydrofolic acid, 5-formyl-tetrahydrofolic acid and their pharmaceutically acceptable salts for use in the therapy of depressive disturbances
The present invention refers to the use of 5-methyltetrahydrofolic acid, of 5-formyltetrahydrofolic acid and of their pharmaceutically acceptable salts for the preparation of controlled release...
|
|
|
5536505 |
Controlled release matrix system using cellulose acetate/poly-2-ethyl-2-oxazoline blends
This invention relates to a controlled release matrix system comprising a homogenous mixture of poly-2-ethyl-2-oxazoline, cellulose acetate having a degree of substitution for acetyl of from about...
|
|
|
5529777 |
Hydrogel microencapsulated vaccines
Water soluble polymers or polymeric hydrogels are used to encapsulate antigen to form vaccines. The antigen is mixed with a polymer solution, microparticles are formed of the polymer and antigen,...
|
|
|
5525354 |
Pharmaceutical preparation and process for its manufacture
In a pharmaceutical preparation for oral use containing a pharmacologically acceptable salt of a bisphosphonic acid, the improvement comprising: a drug delivery form of the preparation which is...
|
|
|
5520931 |
Controlled release morphine preparation
The present invention concerns an oral morphine preparation having essentially complete bioavailability and, for the major part of the dissolution, an essentially zero order and essentially pH...
|
|
|
5521091 |
Compositions and method for destroying hydrogen peroxide on contact lens
Compositions and methods for destroying hydrogen peroxide, for example, contact lens disinfecting amounts of hydrogen peroxide, are disclosed. The present invention utilizes non-mammalian-derived...
|
|
|
5512290 |
Compositions containing 2-acetyl-1-pyrroline
A powder-form composition of 2-acetyl-1-pyrroline incorporated with a support of maltodextrin and/or cyclodextrin. The composition is prepared by hydrolyzing a 2-(1-alkoxyethenyl)-1-pyrroline with...
|
|
|
5510114 |
Slow release pharmaceutical composition containing a bile acid as an active ingredient
A slow-release pharmaceutical composition containing a bile acid as active ingredient and comprising at least one bioadhesive substance and at least one high specific gravity substance, an aliquot...
|
|
|
5508042 |
Controlled release oxycodone compositions
A method for substantially reducing the range in daily dosages required to control pain in approximately 90% of patients is disclosed whereby an oral solid controlled release dosage formulation...
|
|
|
5505963 |
Slow release pharmaceutical preparation
A method of preparing pharmaceutical preparations for oral administration, free of organic solvents. The method employs solidified melt granulates of an active ingredient in admixture with a...
|
|
|
RE35162 |
Rumen and other stomach chamber bypass nutrients and methods of fabrication
A stomach chamber bypass nutrient comprises a beadlet fabricated in two steps having two regions, a first region having the desired nutrient and a second region including fats and calcium based...
|
|
|
5487900 |
Stabilized vitamin D preparation
Heat-labile vitamin D is dispersed in a basic polymer and an excipient readily soluble in an organic solvent to provide a pharmaceutical composition. The composition exhibits reduced isomerization,...
|
|
|
5486364 |
Readily available konjac glucomannan as a sustained release excipient
A solid dosage form, such as a pharmaceutical tablet, containing a rapidly hydratable konjac glucomannan sustained release excipient such as clarified konjac, cryogenically ground konjac and...
|